Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy
Background: The estimation of mortality risk among patients diagnosed with advanced cancer provides important information for clinicians and patients in clinical practice. Currently, gemcitabine-based chemotherapy regimens are the standard treatment for patients with advanced biliary tract cancer (B...
Main Authors: | Chiao-En Wu, Wen-Kuan Huang, Wen-Chi Chou, Chia-Hsun Hsieh, John Wen-Cheng Chang, Cheng-Yu Lin, Chun-Nan Yeh, Jen-Shi Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/13/3139 |
Similar Items
-
Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience
by: Chiao-En Wu, et al.
Published: (2020-05-01) -
Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer:A Retrospective Study
by: Kazuhito Mita, et al.
Published: (2010-12-01) -
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
by: Chiao-En Wu, et al.
Published: (2020-10-01) -
A nomogram to predict overall survival for biliary tract cancer
by: Song W, et al.
Published: (2018-06-01) -
Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study
by: Gao H, et al.
Published: (2021-01-01)